A Phase I Trial for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide.
Phase of Trial: Phase I
Latest Information Update: 29 Oct 2016
At a glance
- Drugs Eflornithine (Primary) ; Etoposide
- Indications Neuroblastoma
- Focus Adverse reactions; Biomarker
- 10 May 2016 Status changed from active, no longer recruiting to completed.
- 02 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Apr 2012 Planned End Date changed from 1 Jun 2012 to 1 Jun 2016 a reported by ClinicalTrials.gov.